
## Quality Innovation Center

## Clinical Guideline Flowchart for Treating Psoriasis Patients Using Biologics

continued on next page

## Is the patient a candidate for systemic therapy? At least one of the following criteria: Moderate to severe psoriasis Disease involving special areas Assess medical history\*, pregnancy/nursing status in applicable patients, laboratory evaluation\*\*, and determine presence of any contraindications. Refer to supplementary table for pregnancy safety of biologic therapies and a list of contraindications. \*See supplementary for information related to biologic therapy baseline screening, and vaccines, as well as its use during surgical procedures \*\*Includes CBC, CMP, TB Test (referral for chest radiograph if necessary), Hepatitis B and C, HIV Test\*\*\*, IBD (IL-17) \*\*\*Based on patient history Based on the patient's initial screening is the patient qualified to receive biologic therapy? **TNF-Alpha Inhibitor** IL-12/23 Inhibitor **IL-17 Inhibitor IL-23 Inhibitor** • ETN, IFX, ADA, CZP UST • SKB, BRO, IXE • GUS, RZB, TIL NO YES -Initiate biologic therapy based on loading dose\* Consider an alternative therapy such as topical, systemic non-biologic, phototherapy, or combination \*See supplementary table for loading dose information therapy for the treatment of psoriasis disease Determine if specialist referral is required to manage patient's systemic issues, if necessary refer patient to corresponding specialist or PCP for abnormal lab results or management of contraindications Was the therapy effective and safe after continuous use? See supplementary table for the suggested period of time to assess efficacy and safety, as well as a list of possible adverse effects. NO -– YES – Consider switching to another biologic or another If the therapy was efficacious and safe continue with class of biologics, especially if side-effects develop, or maintenance therapy and conduct ongoing monitoring. If the to different therapy modalities (topical, phototherapy, or therapy was mildly efficacious consider combination therapy. systemic non-biologic agents) See supplementary table for a list of possible combination therapies

## Clinical Decision Pathway for Treating Psoriasis Patients Using Biologics



For more information, see: aad.org

